Oncology Experts Share Perspectives on mTOR in Cancer

The science behind mTOR's role as a regulator of many cell processes - and its potential as a therapeutic target - is complex. The medical community's understanding of this science and its clinical implications is constantly evolving. In this section, your peers in the research and clinical fields of oncology share their knowledge and perspectives on targeting mTOR and the value that mTOR inhibition may offer in an oncology therapeutic regimen.

The physician views expressed do not necessarily reflect the views of other physicians.

Clinician Perspectives
Clinical points of view from leading oncologists on how mTOR may be integrated into a cancer treatment plan, the growing knowledge of mTOR as a therapeutic target, and mTOR's potential impact on evidence-based medicine.
Mantle Cell Lymphoma Q&A with Mark Kirschbaum, M.D. Director, New Drug Development, Department of Hematological Malignancies/HCT, City of Hope National Cancer Center, and Staff Physician, Department of Hematology/BMT, City of Hope National Cancer Center Neuroendocrine Tumor (NET) and mTOR Q&A with Lowell Anthony, MD Director, Gastrointestinal and Neuroendocrine Oncology, Louisiana State University Health Sciences Center mTOR Q&A with Michael Atkins, MD Director of Cutaneous Oncology and Biologic Therapy Programs and Clinical Research, Beth Israel Deaconess Medical Center and Professor, Department of Medicine, Harvard Medical School

Clinician Perspectives

Clinical points of view from leading oncologists on how mTOR may be integrated into a cancer treatment plan, the growing knowledge of mTOR as a therapeutic target, and mTOR's potential impact on evidence-based medicine.

Dr. Mark Kirschbaum Mantle Cell Lymphoma Q&A with Mark Kirschbaum, M.D.
Director, New Drug Development, Department of Hematological
Malignancies/HCT, City of Hope National Cancer Center, and Staff Physician,
Department of Hematology/BMT, City of Hope National Cancer Center

Dr. Lowell Anthony Neuroendocrine Tumor (NET) and mTOR Q&A with Lowell Anthony, MD
Director, Gastrointestinal and Neuroendocrine Oncology,
Louisiana State University Health Sciences Center

Dr. Michael Atkins mTOR Q&A with Michael Atkins, MD
Director of Cutaneous Oncology and Biologic Therapy Programs and Clinical Research, Beth Israel Deaconess Medical Center and Professor, Department of Medicine, Harvard Medical School

Research Scientist Perspectives
Answers from researchers who are at the forefront of work that is expanding our knowledge of mTOR's structure and functions in normal cells, the role mTOR plays in cancer, and the role mTOR inhibition may play in cancer treatment.
mTOR Q&A with William Sellers, MD Global Head of Oncology Novartis Institutes for Biomedical Research

Peer Perspectives